Format

Send to

Choose Destination
Pharmacogenomics. 2019 Jan 10. doi: 10.2217/pgs-2018-0138. [Epub ahead of print]

Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.

Author information

1
Department of Pharmacy, Fujian Provincial Hospital, Provincial Clinical Medicine College of Fujian Medical University, Fuzhou 350001, Fujian Province, PR China.
2
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, PR China.
3
Department of Oncology, Fujian Provincial Hospital, Provincial Clinical Medicine College of Fujian Medical University, Fuzhou 350001, Fujian Province, PR China.
4
The School of Pharmacy, Fujian Medical University, Fuzhou 350001, Fujian Province, PR China.

Abstract

AIM:

To assess the cost-effectiveness of UGT1A1*6/*28 genotyping compared with no genotyping or no dose adjustment before irinotecan administration in China.

MATERIALS & METHODS:

A decision tree model was developed to evaluate costs and health outcomes represented as quality-adjusted life years gained. Model inputs for the frequency of genotypes, the probability of neutropenia under FOLFIRI chemotherapy and direct costs and utilities were obtained from published sources. One-way sensitivity analyses were performed.

RESULTS:

The strategy of genotyping with dose reduction dominated all remaining strategies. Compared with the strategies of no genotyping and genotyping with unchanged dose, it resulted in only marginal quality-adjusted life year increases (0.0011 and 0.0012) but a cost reduction of $651.12 and $805.22 per patient, respectively. One-way sensitivity analyses revealed that the model was relatively robust.

CONCLUSION:

UGT1A1*6/*28 genotyping was cost saving for Chinese colorectal cancer patients.

KEYWORDS:

; FOLFIRI; colorectal cancer; cost–effectiveness; irinotecan

PMID:
30628534
DOI:
10.2217/pgs-2018-0138

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center